Genetic susceptibility to immune-related adverse events among melanoma patients treated with ipilimumab.

被引：0
|
作者：
Pluta, John [1 ]
Qian, Lu [2 ]
D'Andrea, Kurt [1 ]
Duan, Chunzhe [3 ]
Weathers, Benita [1 ]
Wind-Rotolo, Megan [4 ]
Kanetsky, Peter [5 ]
Nathanson, Katherine [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Roche Holding AG, Shanghai, Peoples R China
[4] Bristol Myers Squib, New York, NY USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1352
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Correlates of toxicity in metastatic melanoma patients treated with ipilimumab.
    Valpione, Sara
    Pigozzo, Jacopo
    Pasquali, Sandro
    Piccin, Luisa
    Mocellin, Simone
    Campana, Luca Giovanni
    Chiarion-Sileni, Vanna
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Nivolumab in melanoma: immune-related adverse events and efficacy
    Reactions Weekly, 2019, 1735 (1) : 11 - 11
  • [23] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [24] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sandigursky, Sabina
    Mor, Adam
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (10)
  • [25] Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sabina Sandigursky
    Adam Mor
    Current Rheumatology Reports, 2018, 20
  • [26] THE EFFECT OF CANNABIS CONSUMPTION ON IMMUNE RELATED ADVERSE EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB NIVOLUMAB COMBINATION THERAPY
    Silman, Yael Steinberg
    Eshet, Lia
    Kennett, Ron
    ben Ami, Sarah
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [27] Correlation between immune-related adverse events and outcomes in nivolumab/ipilimumab combination therapy for metastatic melanoma
    Rauwerdink, Daan
    Frederick, Dennie T.
    Sharova, Tatyana
    Marie, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [28] Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program
    Jeroen, de Filette
    Yanina, Jansen
    Max, Schreuer
    Hendrik, Everaert
    Brigitte, Velkeniers
    Bart, Neyns
    Bert, Bravenboer
    ACTA CLINICA BELGICA, 2016, 71 : 19 - 19
  • [29] IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH TREMELIMUMAB (CP-675,206)
    Wallis, N.
    Bulanhagui, C. A.
    ElSawah, G.
    Pavlov, D.
    Gomez-Navarro, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 242 - 242
  • [30] Immune-related adverse events (irAEs) with ipilimumab treatment of advanced melanoma: A single institution review.
    Myrdal, Caitlyn Nicole
    McBride, Ali
    Hsu, Chiu-Hsieh
    Sundararajan, Srinath
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345